Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer

Stopped early · Phase 2/Phase 3

Conditions studied: Non-small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Metastatic

In brief

The purpose of this study is to determine whether combining ganetespib (STA-9090) with docetaxel is more effective than docetaxel alone in the treatment of subjects with advanced non-small cell lung cancer.

Key facts

Study ID

NCT01348126

Run by

Synta Pharmaceuticals Corp.

People needed

385

Starts

2011-05-01

Expected to finish

2015-10-01

Last updated by the study team

2015-11-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• confirmed diagnosis of NSCLC
• Stage IIIB or IV NSCLC
• ECOG Performance Status 0 or 1
• Prior therapy defined as 1 prior systemic therapy for advanced disease
• measurable disease
• Radiologic evidence of disease progression following most recent prior treatment.
• Adequate hematologic, hepatic, renal function

You may not qualify if…

• Active or untreated CNS metastases
• Active malignancies other than NSCLC within the last 5 years with the exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri or basal or squamous cell carcinoma of the skin
• Serious cardiac illness or medical conditions
• Pregnant or lactating women
• Uncontrolled intercurrent illness

Where it is running

• Synta Pharmaceuticals Investigative Site — Santa Monica, California, United States
• Synta Pharmaceuticals Investigative Site — Atlanta, Georgia, United States
• Synta Pharmaceuticals Investigative Site — Chicago, Illinois, United States
• Synta Pharmaceutials Investigative Site — Boston, Massachusetts, United States
• Synta Pharmaceuticals Investigative Site — Winston-Salem, North Carolina, United States
• Synta Pharmaceuticals Investigative Site — Kettering, Ohio, United States
• Synta Pharmaceuticals Investigative Site — Portland, Oregon, United States
• Synta Pharmaceuticals Investigative Site — Brussels, Belgium
• Synta Pharmaceuticals Investigative Site — Jette, Belgium
• Synta Pharmaceuticals Investigative Site — Yvoir, Belgium
• Synta Pharmaceuticals Investigative Site — Banja Luka, Bosnia and Herzegovina
• Synta Pharmaceuticals Investigative Site — Mostar, Bosnia and Herzegovina
• Synta Pharmaceuticals Investgative Site — Sarajevo, Bosnia and Herzegovina
• Synta Pharmaceuticals Investigative Site — Sarajevo, Bosnia and Herzegovina
• Synta Pharmaceuticals Investigative Site — Tuzla, Bosnia and Herzegovina
• Synta Pharmaceuticals Investigative Site — Hamilton, Canada
• Synta Pharmaceuticals Investigative Site — Montreal, Canada
• Synta Pharmaceuticals Investigative Site — Montreal, Canada
• Synta Pharmaceuticals Investigative Site — Ottawa, Canada
• Synta Pharmaceuticals Investigative Site — Pula, Croatia
• Synta Pharmaceuticals Investigative Site — Split, Croatia
• Synta Pharmaceuticals Investigative Site — Zagreb, Croatia
• Synta Pharmaceuticals Investigative Site — Prague, Czechia
• Synta Pharmaceuticals Investigative Site — Halle, Germany
• Synta Pharmaceuticals Investigative Site — Tucson, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.